#UMED-TECH-002
SUMMARY
The invention concerns a method for in vitro diagnosis of multiple sclerosis (MS ) based on the absolute count of lymphocytes with the CD49d+CD154+ phenotype autoreactive toward myelin proteins after the exposure of Peripheral Blood Mononuclear Cells to myelin peptides in the in vitro conditions. The method is useful for the early diagnosis of multiple sclerosis.
BACKGROUND
It is estimated that approximately 2.5 million people are affected by this disease worldwide, including around 45,000 in Poland. This represents a significant social problem, as the disease often excludes patients from social and professional life. One of the most critical challenges faced by neurologists is the early diagnosis of multiple sclerosis (MS), compounded by the lack of laboratory tests that can definitively confirm the disease.
The proposed test is based on the highly specific immune response of MS patients to autoantigens, specifically myelin proteins. The test involves the assessment of the expansion of a lymphocyte subpopulation with the CD49d⁺CD154⁺ phenotype within the total population of peripheral blood mononuclear cells (PBMCs). Due to the fact that this type of immune response is highly specific, the proposed test is also expected to exhibit high specificity (i.e., a low rate of false-positive results). Furthermore, since the test requires a flow cytometer—a sensitive device capable of analyzing individual cells—it is also expected to demonstrate high sensitivity (i.e., a low rate of false-negative results).
FEATURES AND KEY BENEFITS
- High diagnostic specificity and sensitivity – based on a unique immune response to myelin proteins, minimizing false positives and false negatives.
- Non-invasive and patient-friendly – the test is based on peripheral blood analysis and can be performed without invasive procedures.
- Early and reliable detection – enables earlier diagnosis of multiple sclerosis compared to currently available methods.
- First class solution – the method addresses a significant unmet clinical need, offering a novel diagnostic approach not covered by existing tests.
REFERENCES
P.445027 https://ewyszukiwarka.pue.uprp.gov.pl/search/pwp-details/P.445027
PCT patent application PCT/PL2024/050037- https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2024248642
AVAILABLE
for licensing
CONTACT
Medical University of Łódź, The Center for Innovation and Technology Transfer Ciitt@umed.lodz.pl
Back